Below is a statement from Bayer Ireland on Brexit supplies (Sep. 2019):
Shortly after the UK voted to leave the EU in June 2016, Bayer Ltd. started work on preparations to ensure continuity of supply of our products in Ireland. Our Brexit-readiness team has representation from a number of core areas, including supply chain and regulatory affairs.
Our scenario planning has included ‘No Deal’ as a potential outcome, so that we are fully prepared for all eventualities. This has included a comprehensive mix of measures that are designed to mitigate the most significant risks identified for the period immediately prior to and after the 31st October 2019. A key mitigation strategy is that we have finalised an alternative route through the EU for products which are currently supplied to Ireland via the UK.
Following an extensive review with the distributor to decide the best route for Xofigo, we can confirm that we will continue to use the existing route of Brussels-East Midlands-Dublin for this product. As East Midlands airport is a transit airport (neutral zone), there would be no import/export activities required. We will continue to monitor this distribution route for Xofigo very closely.
There is no need for hospitals, pharmacists or patients to order extra quantities of medicines or for doctors to issue additional prescriptions. Doing so could disrupt existing stock levels and hamper the supply of medicines for other patients.
If you have any further queries regarding availability of stock please contact customer service at 012061520 or email@example.com
Managing Director and CDH PH Ireland